Status:
COMPLETED
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
de Novo Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Sacubitril/valsartan cohort:
- Prescribed sacubitril/valsartan within the identification period.
- With at least one International Classification of Diseases, 9th Revision (ICD)-9 or 10th Revision (ICD-10) code for diagnosis of HF within 30 days prior to the index date (including index date), that had non-missing sex and year of birth data.
- Active in the database for 759 days prior to index.
- With left ventricular ejection fraction (LVEF) ≤ 40% known prior to index day (including index date).
- That were treated as part of the integrated delivery network (IDN).
- ACEi/ARB cohort:
- Prescribed ACEi or ARB within the identification period.
- With at least one ICD-9 or ICD-10 code for diagnosis of HF within 30 days prior to the index date (including index date), that have non-missing sex and year of birth data.
- Active in the database for 759 days prior to index.
- With LVEF ≤ 40% known prior to index day (including index date).
- That were treated as part of the IDN.
- Exclusion Criteria
- Sacubitril/valsartan cohort:
- That were \< 18 years old at index date.
- That were prescribed sacubitril/valsartan within the baseline period or identification period (whichever was earlier) at any time prior to the index date (excluding).
- With one or more ICD-9 or ICD-10 codes for diagnosis of HF within the baseline period, excluding the 30 days prior to index in which HF was initially identified (patient should have had no prior history of HF).
- That were prescribed ACEi/ARB \> 2 days before index date, and within 30 days after a HF diagnosis during the identification period (i.e. any patient included in the ACEi/ARB cohort with an earlier index date, regardless of whether LVEF was ≤ 40% or \> 40%)
- With LVEF ≤ 10% as the closest value to index date (including).
- ACEi/ARB cohort:
- That were \< 18 years old at index date.
- That were prescribed sacubitril/valsartan within the baseline period or identification period (whichever was earlier) at any time prior to the index date, on the index date, or until ≤ 2 days after the index date.
- With one or more ICD-9 or ICD-10 codes for diagnosis of HF within the baseline period, excluding the 30 days prior to index in which HF was initially identified (patient should have had no prior history of HF).
- With LVEF ≤ 10% as the closest value to index date (including).
Exclusion
Key Trial Info
Start Date :
November 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 19 2022
Estimated Enrollment :
9870 Patients enrolled
Trial Details
Trial ID
NCT05963282
Start Date
November 29 2021
End Date
July 19 2022
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936